Basal cell nevus syndrome

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 160-166

  High, Alec ^a   Zedan, Walid ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

BCC; BCNS; Gorlin syndrome; Hedgehog medulloblastoma; NBCCS; PTCH; Smoothened

Indexed keywords

CYCLOPAMINE; GENE PRODUCT; PROTEIN BMI1; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN PATCHED 1; PROTEIN SMOOTHENED; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOSOMAL DOMINANT INHERITANCE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BINDING SITE; CANCER SUSCEPTIBILITY; CELL CYCLE; CLINICAL FEATURE; DROSOPHILA PATCHED GENE; DRUG TRANSFORMATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HUMAN; LMX1B GENE; MEDULLOBLASTOMA; MUTATIONAL ANALYSIS; NONHUMAN; ODONTOGENIC KERATOCYST; PARALOGY; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; SKIN CARCINOGENESIS; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASAL CELL NEVUS SYNDROME; HUMANS; MEMBRANE PROTEINS; MUTATION; SKIN NEOPLASMS;

EID: 17144365829     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000154108.99236.ed     Document Type: Review

References (59)

1. Locus Link Report: [NCBI website] Available at: http://www.ncbi.nlm.nih. gov/ LocusLink/LocRpt.cgi?l=5726. Accessed October 4th, 2004.
2. Jarish W. Zur lehre von den autgeschwulsten. Archiv Jur Dermatologic und Syphilogic 1894; 28:163-222.
3. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med 1960; 262:908-912.
4. Basal Cell Nevus Syndrome: BCNS [OMIM website] Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=109400. Accessed October 4th, 2004. An excellent source of information. Regularly updated with links.
5. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome: unanswered issues. J Lab Clin Med 1999; 134:551-552.
6. Goldstein AM, Pastakia B, DiGiovanna JJ, et al. Clinical findings in two African-American families with the nevoid basal cell carcinoma syndrome (NBCC). Am J Med Genet 1994; 50:272-281.
7. Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981; 61:497-503.
8. Bazex A, Dupre A, Christol B. Genodermatose complexe de type indetermine associant une hypotrichose, un etat atrophodermique generalise et des degenerescences cutanees multiples (epitheliomas-basocellulaires). Bull Soc Franc Derm Syph 1964; 71:206.
9. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69:111-117.
10. Levanat S, Pavelic B, Crnic I, et al. Involvement of PTCH gene in various non-inflammatory cysts. J Mol Med 2000; 78:140-146.
11. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-851.
12. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668-1671.
13. Chidambaram A, Goldstein AM, Gailani MR, et al. Mutations in the human homologue of the Drosophila patched gene in Caucasian and African-American nevoid basal cell carcinoma syndrome patients. Cancer Res 1996; 56:4599-4601.
14. Unden AB, Holmberg E, Lundh-Rozell B, et al. Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: Different in vivo mechanisms of PTCH inactivation. Cancer Res 1996; 56:4562-4565.
15. Lench NJ, Telford EA, High AS, et al. Characterisation of human patched germ line mutations in naevoid basal cell carcinoma syndrome. Hum Genet 1997; 100:497-502.
16. Boutet N, Bignon YJ, Drouin-Garraud V, et al. Spectrum of PTCH1 mutations in French patients with Gorlin syndrome. J Invest Dermatol 2003; 121:478-481. These authors propose that mutation c1208-1209delAT is the first truly recurrent mutation identified in the PTCH gene. Patients bearing this mutation have a different clinical outcome, which pinpoints the possible involvement of modifier genes.
17. Nagao K, Fujii K, Yamada M, Miyashita T. Identification of a novel polymorphism involving a CGG repeat in the PTCH gene and a genome-wide screening of CGG-containing genes. J Hum Genet 2004; 49:97-101. PTCH has a CGG triplet repeat located 4 bp upstream of the first methionine codon. These authors suggest that the repeat length potentially affects the levels of gene expression.
18. Midro AT, Panasiuk B, Turner Z, et al. Interstitial deletion 9q22.32-q33.2 associated with additional familial translocation (9;17)(q34.11;p11.2) in a patient with Gorlin-Goltz syndrome and features of nail-patella syndrome. Am J Med Genet 2004; 124:179-191. A useful discussion of the spectrum of the interstitial monosomy 9q22-q33 and BCNS.
19. Mullor JL, Sanchez P, Altaba AR. Pathways and consequences: hedgehog signaling in human disease. Trends Cell Biol 2002; 12:562-569.
20. Ingham PW. Hedgehog signaling: a tale of two lipids. Science 2001; 294:1879-1881.
21. Jeong J, McMahon AP. Cholesterol modification of hedgehog family proteins. J Clin Invest 2002; 110:591-596.
22. Cross SS, Bury JP. The Hedgehog signalling pathways in human pathology. Curr Diagn Pathol 2004; 10:157-168. A good review that clearly sets Hedgehog pathways in various species in context.
23. Cohen MM Jr. The Hedgehog Signaling Network. Am J Genet 2003; 123A:5-28. A comprehensive review of the HH signaling pathway. A lot of detail on related conditions is given.
24. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001; 61:513-516.
25. Oniscu A, James RM, Morris RG. Expression of Sonic hedgehog pathway genes is altered in colonic neoplasia. J Pathol 2004; 203:909-917.
26. Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001; 10:757-762.
27. Reifenberger J, Arnold N, Kiechle M, et al. Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. J Invest Dermatol 2001; 116:472-474.
28. Wicking C, McGlinn E. The role of hedgehog signalling in tumorigenesis. Cancer Lett 2001; 173:1-7.
29. Tojo M, Kiyosawa H, Iwatsuki K, et al. Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma. Br J Dermatol 2003; 148:892-897. As Gli2b is an isoform spliced at the first splicing site containing a repression domain and consists of an intact activation domain, its overexpression may lead to the upregulation of the Shh signaling pathway, thereby inducing BCCs.
30. Kim MY, Park HJ, Baek SC, et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 2002; 29:1-9.
31. Saldanha G, Shaw JA, Fletcher A. Evidence that superficial basal cell carcinoma is monoclonal from analysis of the Ptch1 gene locus. Br J Dermatol 2002; 147:931-935.
32. Couve-Privat S, Bouadjar B, Avril MF, et al. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res 2002; 62:7186-7189.
33. Grachtchouk V, Grachtchouk M, Lowe L, et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 2003; 22:2741-2751. These authors suggest that the levels of HH pathway activation and G1 cyclins are determinants of tumor phenotype, and implicate deregulated hedgehog signaling in the genesis of human basaloid follicular hamartomas. Expression of an activated SMO mutant in keratinocytes appears to be insufficient for the development and/or maintenance of full-blown BCCs.
34. Neill GW, Ghali LR, Green JL, et al. Loss of protein kinase Cα expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma. Cancer Res 2003; 63:4692-4697. Two protein kinase C (PKC) isoforms are expressed in BCC and hair follicles. PKCα negatively regulates Gli1 activity. This is important because PKCα is downregulated in BCC, whereas Gli1 is expressed in BCC.
35. Eichberger T, Regl G, Ikram MS, et al. FOXE1, a new transcriptional target of GLI2, is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004; 122:1180-1187. In searching for downstream mediators of GLI2 function in epidermal cells after HH signaling, these authors identified a new GLI2 target gene, FOXE1. This may prove to be one of many.
36. Ågren MA, Kogerman P, Kleman MI, et al. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene 2004; 330:101-114. Further supporting evidence that the various components of the HH signaling pathway are critically dependent on a single functional Gli-binding site.
37. Regl G, Neill GW, Eichberger T, et al. Human GLI2 and GLI1 are part of a positive feedback mechanism in basal cell carcinoma. Oncogene 2002; 21:5529-5539.
38. Sheng H, Goich S, Wang A, et al. Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. Cancer Res 2002; 62:5308-5316.
39. Neill GW, Ghali LR, Green JL, et al. Loss of protein kinase c alpha expression may enhance the tumorigenic potential of gli1 in basal cell carcinoma. Cancer Res 2003; 63:4692-4697.
40. Ikram MS, Neill GW, Regl G, et al. GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol 2004; 122:1503-1509. Experimental evidence for a positive feedback loop between GLI1 and GLI2 that potentiates the Shh signal.
41. Mazzola CA, Pollack IF. Medulloblastoma. Curr Treat Options Neurol 2003; 5:189-198.
42. Weiner HL, Bakst R, Hurlbert MS, et al. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res 2002; 62:6385-6389.
43. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306-310.
44. Leung C, Lingbeek M, Shakhova O, et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428:337-341. A first report highlighting a role for Bmi1-containing polycomb complexes in proliferation of cerebellar precursor cells.
45. Zedan W, Robinson PA, Markham AF, High AS. Expression of the Sonic Hedgehog receptor 'PATCHED' in basal cell carcinomas and odontogenic keratocysts. J Pathol 2001; 194:472-476.
46. Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. Proliferation and genetic studies. Oral Oncol 2002; 38:323-331.
47. Agaram NP, Collins BM, Barnes L, et al. Molecular analysis to demonstrate that odontogenic keratocysts are neoplastic. Arch Pathol Lab Med 2004; 128:313-317.
48. Thosaporn W, Iamaroon A, Pongsiriwet S, et al. A comparative study of epithelial cell proliferation between the odontogenic keratocyst, orthokeratinized odontogenic cyst, dentigerous cyst, and ameloblastoma. Oral Dis 2004; 10:22-26.
49. Koike C, Mizutani T, Ito T, et al. Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene 2002; 21:2670-2678.
50. Sato N, Leopold PL, Crystal RG, et al. Effect of adenovirus mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy induced alopecia. J Natl Cancer Inst 2001; 93:1858-1864.
51. Tsuboi K, Shults CW. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease. Exp Neurol 2002; 173:95-104.
52. Pepinsky RB, Shapiro RI, Wang S, et al. Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J Pharm Sci 2002; 91:371-387.
53. Ahlgren SC, Thakur V, Bronner-Fraser M. Sonic hedgehog rescues cranial neural crest from cell death induced by ethanol exposure. Proc Natl Acad Sci USA 2002; 99:10476-10481.
54. Williams JA, Guicherit OM, Zaharian BI, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003; 100:4616-4621. A patent application, describing the use of cyclopamine to selectively block the Hedgehog pathway for therapeutic purposes, was filed by the Johns Hopkins University School of Medicine and subsequently licensed to CURIS (2003). CURIS has a number of interests in developing drugs that either promote or inhibit signaling activity in the Hedgehog pathway.
55. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406:1005-1009.
56. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by Hedgehog pathway blockade. Science 2002; 297:1559-1561.
57. Park HL, Bai C, Platt KA, et al. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 2000; 127:1593-1605.
58. Tang X, Kim AL, Feith DJ, et al. Omithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1-t-/- mice. J Clin Invest 2004; 113:867-875. α-difluoromethylomithine (DFMO) appears to be a useful inhibitor of ODC and, at least when used topically, appears safe. Mouse and human consumption of DFMO in cancer-chemoprevention studies has revealed no toxic effects, other than ototoxicity at high doses, which was reversible after discontinuation.
59. Kimonis VE, Goldstein AM, Pastakia B. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genetics 1997; 69:299-308.